USRE32534EExpiredUtility

Peptides, process for preparing the same and psychodepressant compositions containing the same

Priority: Oct 27, 1982Filed: Jan 3, 1986Granted: Oct 27, 1987
Est. expiryOct 27, 2002(expired)· nominal 20-yr term from priority
C07K 14/595C07K 5/06113A61K 38/00
7
PatentIndex Score
2
Cited by
18
References
12
Claims

Abstract

This invention provides a peptide represented by the formula R--Tyr(SO.sub.3 H)--Met--Gly--Trp--Met--Asp--W--NH.sub.2 wherein R is HOOC--A--CO--Asp-- (wherein A is lower alkylene), pGlu--Asp--, HOOC--A--CO-- (wherein A is lower alkylene) or ##STR1## and W is Phe or N.sup.α -lower alkyl-Phe, or a salt thereof, process for preparing the peptide and psychodepressant composition containing the peptide. The peptides of the invention are useful as psychodepressant drug, and especially effective for curing schizophrenia.

Claims

exact text as granted — not AI-modified
We claim: 
     
       1. A peptide represented by the formula R--Tyr(SO 3  H)--Met--Gly--Trp--Met--Asp--W--NH 2  wherein R is HOOC--A--CO--Asp-- (wherein A is lower alkylene), pGlu--Asp--, HOOC--A--CO-- (wherein A is lower alkylene) or ##STR7## and W is Phe or N.sup.α -lower alkyl-Phe, or a salt thereof .Iadd.with the proviso that when R is HOOC(CH 2 ) 2  CO--, W is N.sup.α -lower alkyl-Phe.Iaddend..   
     
     
       2. A peptide as defined in claim 1 which is represented by the formula R--Tyr(SO 3  H)--Met--Gly--Trp--Met--Asp--Phe--NH 2  wherein R is HOOC(CH 2 ) 3  CO--Asp-- or pGlu--Asp--, or a salt thereof.   
     
     
       3. A peptide as defined in claim 1 which is represented by the formula R--Tyr(SO 3  H)--Met--Gly--Trp--Met--Asp--W--NH 2  wherein R is HOOC--A--CO-- (wherein A is lower alkylene) or ##STR8## and W is Phe or N.sup.α -lower alkyl-Phe, or a salt thereof .Iadd.with the proviso that when R is HOOC(CH 2 ) 2  CO--, W is N.sup.α -lower alkyl-Phe.Iaddend..   
     
     
       4. A central-nervous-system-suppressing composition for treating patients requiring central-nervous-system-suppression comprising an effective central-nervous-system-suppressing amount of a peptide represented by the formula   R--Tyr(SO.sub.3 H)--Met--Gly--Trp--Met--Asp--W--NH.sub.2     wherein R is HOOC--A--CO--Asp-- (wherein A is a lower alkylene), pGlu--Asp--, HOOC--A--CO-- (wherein A is lower alkylene) or ##STR9## and W is Phe or N.sup.α -lower alkyl-Phe, or a salt thereof, and a pharmacologically acceptable, nontoxic carrier .Iadd.with the proviso that when R is HOOC(CH 2 ) 2  CO--, W is N-lower alkyl-Phe.Iaddend..   
     
     
       5. A composition as defined in claim 4 wherein the peptide is represented by the formula   R--Tyr(SO.sub.3 H)--Met--Gly--Trp--Met--Asp--Phe--NH.sub.2     wherein R is HOOC(CH 2 ) 3  CO--Asp-- or pGlu--Asp--, or a salt thereof.   
     
     
       6. A composition as defined in claim 4 wherein the peptide is represented by the formula .Iadd.R--Tyr(SO 3  H)--Met--Gly--Trp--Met--Asp--W--NH 2  wherein R is HOOC--A--CO-- (wherein A is lower alkylene), or ##STR10## and W is Phe or N.sup.α -lower alkyl-Phe, or a salt thereof with the proviso that when R is HOOC(CH 2 ) 2  CO--, W is N.sup.α -lower alkyl-Phe.Iaddend..   
     
     
       7. A peptide as defined in claim 1 which is represented by the formula:   R--Tyr(SO.sub.3 H)--Met--Gly--Trp--Met--Asp--W--NH.sub.2     wherein R is HOOC--A--CO--Asp-- (wherein A is lower alkylene), pGlu--Asp-- or HOOC--A--CO--  (wherein A is lower alkylene) and W is Phe or N.sup.α -lower alkyl-Phe, or a salt thereof .Iadd.with the proviso that when R is HOOC(CH 2 ) 2  CO--, W is N.sup.α -lower alkyl-Phe.Iaddend..   
     
     
       8. A peptide as defined in claim 7 which is represented by the formula   R--Tyr(SO.sub.3 H)--Met--Gly--Trp--Met--Asp--W--NH.sub.2     wherein R is HOOC--A--CO-- (wherein A is lower alkylene) and W is Phe or N.sup.α -alkyl-Phe, or a salt thereof   .Iadd.with the proviso that when R is HOOC(CH 2 ) 2  CO--, W is N.sup.α -lower alkyl-Phe.Iaddend..   
     
     
       9. A peptide as defined in claim 8 which is represented by the formula   Suc--Tyr(SO.sub.3 H)--Met--Gly--Trp--Met--Asp--MePhe--NH.sub.2     wherein MePhe is N.sup.α -methyl-Phe.   
     
     
       10. A peptide as defined in claim 8 which is represented by the formula   Glt--Tyr(SO.sub.3 H)--Met--Gly--Trp--Met--Asp--Phe--NH.sub.2.     
     
     
       11. A composition as defined in claim 4 wherein the peptide is represented by the formula   R--Tyr(SO.sub.3 H)--Met--Gly--Trp--Met--Asp--W--NH.sub.2     wherein R is HOOC--A--CO--Asp-- (wherein A is lower alkylene), pGlu--Asp-- or HOOC--A--CO-- (wherein A is lower alkylene) and W is Phe or N.sup.α -lower alkyl-Phe, or a salt thereof .Iadd.with the proviso that when R is HOOC(CH 2 ) 2  CO--, W is N.sup.α -lower alkyl-Phe.Iaddend..   
     
     
       12. A composition as defined in claim 11, wherein the peptide is represented by the formula   R--Tyr(SO.sub.3 H)--Met--Gly--Trp--Met--Asp--W--NH.sub.2     wherein R is HOOC--A--CO-- (wherein A is lower alkylene) and W is Phe or N.sup.α -lower alkyl-Phe, or a salt thereof .Iadd.with the proviso that when R is HOOC(CH 2 ) 2  CO--, W is N.sup.α -lower alkyl-Phe.Iaddend..

Join the waitlist — get patent alerts

Track USRE32534E — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.